Want to see GNLX full AI Analyst Report?

Genelux Corp. (GNLX) Price & Analysis

300 Followers

GNLX Stock Chart & Stats

$2.79

-$0.06(-2.24%)

At close: Jan 08 4:00 PM EST

$2.79

-$0.06(-2.24%)

Day’s Range― - ―

52-Week Range$2.29 - $8.54

Previous CloseN/A

Volume23.79K

Average Volume (3M)156.94K

Market Cap

$135.42M

Enterprise Value$100.43M

Total Cash (Recent Filing)$26.21M

Total Debt (Recent Filing)$2.50M

Price to Earnings (P/E)―

Beta0.97

Next Earnings

Aug 18, 2026

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.88

Shares Outstanding44,840,416

10 Day Avg. Volume178,540

30 Day Avg. Volume156,945

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)14.04

Price to Sales (P/S)20261.21

P/FCF Ratio-6.15

Enterprise Value/Market Cap0.74

Enterprise Value/Revenue12.55K

Enterprise Value/Gross Profit-353.63

Enterprise Value/Ebitda-3.13

Forecast

1Y Price Target

$23.50

Price Target Upside742.29% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.82

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Oncolytic Vaccinia PlatformGenelux's proprietary oncolytic vaccinia platform and lead candidates (GEN-1, GEN-2) provide a durable technological moat in oncolytic immunotherapy. If clinical data validate mechanism, platform enables multiple tumor indications, partnerships, and product-line leverage beyond a single asset.

Low Financial LeverageModest reported debt versus equity implies low financial leverage relative to peers, reducing bankruptcy risk and interest burden. This balance-sheet strength improves strategic optionality to invest in trials or seek partnerships without immediate creditor pressure over the next several months.

Established $100M ATM Financing ProgramThe $100M ATM program creates a durable capital-raising mechanism that can be tapped proactively to fund R&D and trials. By providing flexible access to equity markets, management can extend runway and pace clinical programs without needing one-time dilutive financings tied to immediate cash shortfalls.

Bears Say

High Cash Burn And Negative Free Cash FlowSustained multi‑million dollar negative operating and free cash flow indicates the company cannot self-fund development. Persistent burn forces frequent external raises, compresses strategic choices, and may require slowing or reprioritizing programs if capital access tightens over the next several quarters.

Minimal Recurring RevenueWith essentially no product revenue, the business model remains fully development‑stage and dependent on clinical milestones. Long-term sustainability hinges on successful trials and commercialization, making current operations vulnerable to setbacks and prolonging reliance on non‑operational funding sources.

Dependence On External Financing And Dilution RiskThe company's reliance on equity financings and the new ATM increases shareholder dilution risk and ties strategic pacing to market access. Repeated raises can dilute long‑term returns and create execution uncertainty if investor appetite weakens during clinical readout cycles over the next 2–6 months.

Genelux Corp. News

Buy Rating Reaffirmed on Olvi-Vec Progress and Data Outlook; $31 Price Target Maintained

Genelux Corp., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from...

2M ago

GNLX

Genelux reports Q1 EPS (20c), consensus (19c)

“As we build on our momentum entering 2026, we remain focused on disciplined execution of our registrational program....

2M ago

GNLX

Buy Rating Backed by Pivotal Olvi-Vec Ovarian Cancer Trial Progress and Multi-Indication Upside Potential

Maxim Group analyst Jason McCarthy has maintained their bullish stance on GNLX stock, giving a Buy rating yesterday....

4M ago

GNLX

Genelux price target lowered to $20 from $23 at Benchmark

Benchmark lowered the firm’s price target on Genelux (GNLX) to $20 from $23 and keeps a Speculative Buy...

4M ago

GNLX

Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Genelux Corp., retaining the price target of...

4M ago

GNLX

Genelux Establishes $100 Million At-The-Market Equity Program

Genelux Corp. ( ($GNLX) ) has issued an announcement. On March 19, 2026, Genelux Corporation entered into a...

4M ago

GNLX

Genelux Updates Corporate Presentation for Investors and Stakeholders

The latest announcement is out from Genelux Corp. ( ($GNLX) ). On February 2, 2026, Genelux Corporation updated...

5M ago

GNLX

Genelux Announces Underwritten Public Offering to Raise Capital

Genelux Corp. ( ($GNLX) ) has shared an update. On January 8, 2026, Genelux Corporation entered into an...

6M ago

GNLX

Genelux prices 6.67M shares at $3.00 in underwritten public offering

Genelux (GNLX) Corporation announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock...

6M ago

GNLX

Genelux announces common stock offering, no amount given

Genelux (GNLX) Corporation announced that it has commenced a proposed underwritten public offering of its common stock. All...

6M ago

GNLX

Genelux data update indicates disease early control, says H.C. Wainwright

Genelux (GNLX) reported updated interim data showing IV Olvi-Vec plus platinum chemotherapy achieved a 33% overall response rate...

6M ago

GNLX

$Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer$

Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Genelux Corp., retaining the price target of...

6M ago

GNLX

Genelux Reports Encouraging Interim Data for Olvi-Vec Trials

Genelux Corp. ( ($GNLX) ) just unveiled an update. On January 5, 2026, Genelux Corporation reported interim data...

6M ago

GNLX

Genelux reports interim data of systemic administration of Olvi-Vec

Genelux (GNLX) announced interim results from two ongoing trials – Phase 1b/2 SCLC and Phase 2 VIRO-25 –...

6M ago

GNLX

GNLX FAQ

What was Genelux Corp.’s price range in the past 12 months?

Genelux Corp. lowest stock price was $2.29 and its highest was $8.54 in the past 12 months.

What is Genelux Corp.’s market cap?

Genelux Corp.’s market cap is $135.42M.

When is Genelux Corp.’s upcoming earnings report date?

Genelux Corp.’s upcoming earnings report date is Aug 18, 2026 which is in 41 days.

How were Genelux Corp.’s earnings last quarter?

Genelux Corp. released its earnings results on May 13, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.195 by -$0.005.

Is Genelux Corp. overvalued?

According to Wall Street analysts Genelux Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Genelux Corp. pay dividends?

Genelux Corp. does not currently pay dividends.

What is Genelux Corp.’s EPS estimate?

Genelux Corp.’s EPS estimate is -0.2.

How many shares outstanding does Genelux Corp. have?

Genelux Corp. has 44,840,416 shares outstanding.

What happened to Genelux Corp.’s price movement after its last earnings report?

Genelux Corp. reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.195. Following the earnings report the stock price went up 7.407%.

Which hedge fund is a major shareholder of Genelux Corp.?

Currently, no hedge funds are holding shares in GNLX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Genelux Corp. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-165.18%

Trailing 12-Months

Asset Growth

-16.96%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genelux Corp.

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.

Genelux Corp. (GNLX) Earnings & Revenues

Historic Earnings Reports

GNLX Stock 12 Month Forecast

Average Price Target

$23.50

▲(742.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","32":"$32","8.75":"$8.75","16.5":"$16.5","24.25":"$24.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.75,16.5,24.25,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.9,5.061538461538461,7.223076923076924,9.384615384615385,11.546153846153848,13.70769230769231,15.869230769230771,18.03076923076923,20.192307692307693,22.353846153846156,24.51538461538462,26.676923076923078,28.83846153846154,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.9,4.484615384615385,6.069230769230769,7.653846153846155,9.23846153846154,10.823076923076924,12.40769230769231,13.992307692307694,15.576923076923078,17.161538461538463,18.746153846153845,20.33076923076923,21.915384615384617,{"y":23.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.9,3.9076923076923076,4.915384615384616,5.923076923076923,6.930769230769231,7.938461538461539,8.946153846153846,9.953846153846154,10.961538461538462,11.96923076923077,12.976923076923077,13.984615384615385,14.992307692307692,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.97,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >